(Q62025340)
Statements
A First-in-Human, Single Ascending Dose, Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Subcutaneously Administered GX-G6 in Male Healthy Volunteers. (English)
0 references
31 August 2017
0 references
6 June 2018
0 references
48
0 references
18 year
0 references
50 year
0 references